A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
Inclusion Criteria:
Exclusion Criteria:
Ann Arbor, Michigan 48109-5000, United States
Ciudad Autonoma Buenos Aires, C1120AAC, Argentina
Ciudad Autonoma Buenos Aires, C1425AWK, Argentina
Ciudad Autonoma de Buenos Aire, C1202ABB, Argentina
Ciudad de Buenos Aires, 1431, Argentina
Ciudad de Buenos Aires, C1221Adc, Argentina
Campinas, 13060-904, Brazil
São José do Rio Preto, 15090-000, Brazil
Floridablanca, 6810002, Colombia
Lima - Barranco, Barranco 15063, Peru
KwaZulu-Natal, 4030, South Africa
KwaZulu-Natal, 4030, South Africa
KwaZulu-Natal, 4110, South Africa
Vulindlela, 4013, South Africa
Westdene Johannesburg Gauteng, 2092, South Africa